Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 3/20 | 0.45 |
| ▸ | METAP1 | P53582 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628527 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL7366366 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL26966061 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL19682744 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL6460441 | 0.90 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL6460442 | 0.90 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL5028930 | 0.87 | ALOX5 (0.48) | ALOX5ALDH1A1METAP2METAP1CYP2C9 | |
| SCHEMBL6464059 | 0.86 | ALDH1A1 (0.49) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL6464051 | 0.86 | ALDH1A1 (0.49) | SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1 | |
| SCHEMBL19682577 | 0.82 | SLC1A1 (0.42) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| CN-109563057-B | Sulfonamide compound or salt thereof | 大鹏药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-4940709-A | PLATELET ACTIVATING FACTOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-07-10 | — | — | US | disclosed |
| EP-0181152-B1 | PIPERAZINE COMPOUND AS PAF-ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-13 | — | — | EP | disclosed |
| US-4806538-A | ANTICOAGULANT, HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-02-21 | — | — | US | disclosed |
| EP-0181152-A1 | Piperazine compound as PAF-antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | SLC1A3 3150/4885SLC1A2 4244/4885SLC1A1 3154/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | SLC1A3 4261/4885SLC1A2 4673/4885SLC1A1 4257/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC1A3 4472/4885SLC1A2 4787/4885SLC1A1 4654/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | SLC1A3 3688/4885SLC1A2 4510/4885SLC1A1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.